{"anticipatedPostingDate":"2027-12","denomUnitsSelected":"Participants","description":"DCR was defined as the percentage of participants with confirmed CR, PR, or stable disease (SD or non-CR/non-PD) according to RECIST v1.1 as assessed by investigator. As per RECIST v1.1, CR: disappearance of all target (T) lesions and non-target (NT) lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR: at least \\>=30 % decrease in the SOD of target lesions (longest for non-nodal target lesions and the short axes for nodal target lesions), taking as reference the baseline sum diameters. PD: at least \\>=20% relative increase in SOD of target lesions taking as reference the smallest sum on study (including baseline sum if that is the smallest on study). SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD while on study and cannot have met criteria for PD previously.","reportingStatus":"NOT_POSTED","timeFrame":"From the first dose study treatment until PD or death, whichever occurred first (approximately 52.7 months)","title":"Confirmed Disease Control Rate (DCR) as Assessed by Investigator","type":"SECONDARY"}